Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its pharmaceutical industry layout and accelerate the research and development of health food [1][2] - The subsidiary is registered with a capital of 10 million RMB and will focus on various health food production and sales, including special medical purpose formula foods and infant formula foods [1][2] - This investment aligns with the company's strategic development plan to improve its diversified product matrix and aims to enhance overall profitability and risk resistance [1][2] Group 2 - The establishment of the subsidiary is not expected to harm the interests of the company or its shareholders and will not negatively impact the company's operations [2] - The company plans to conduct its business activities prudently and in compliance with regulations, aiming for favorable investment returns while being aware of potential market and policy risks [2]

证券代码：002873 证券简称：新天药业 公告编号：2025-053 根据《深圳证券交易所股票上市规则》、《公司章程》等相关规定，本次对 外投资金额未达到董事会或股东会的审议标准，无需提交董事会和股东会审议。 本次投资事项不涉及关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 | 名称 | 贵州中道中医药健康科技有限公司 | | --- | --- | | 统一社会信用代码 | 91520112MAEURRW39J | | 类型 | 有限责任公司（非自然人投资或控股的法人独资） | | 住所 | 贵州省贵阳市乌当区新创路街道新添大道 号 114 | | 法定代表人 | 魏茂陈 | 二、设立全资子公司的基本情况 贵阳新天药业股份有限公司 关于对外投资设立全资子公司并完成 工商注册登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 贵阳新天药业股份有限公司（以下简称"公司"）为进一步加大综合性医药 产业布局，加快实现保健食品研发与成果转化，完善公司多元化产品矩阵，促进 市场销售规模提升，公司以自有资金人民币 ...

Core Viewpoint - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its product matrix and overall profitability [1] Group 1: Investment Details - The investment amount is 10 million RMB, aimed at promoting the research and development of health food and its transformation into products [1] - The registered capital of Zhongdao Health is exactly 10 million RMB, with Wei Maochen as the legal representative [1] - The establishment date of the subsidiary is September 1, 2025, and it has received a business license from the Market Supervision Administration of Wudang District, Guiyang City [1] Group 2: Business Scope - The business scope of the new subsidiary includes the production of health food, special medical purpose formula food, infant formula food, food additives, dairy products, beverages, and food sales [1] - This diversification aims to enhance the company's overall profitability and risk resistance [1] - The investment aligns with the company's strategic goal of becoming a comprehensive pharmaceutical enterprise [1]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction, which enhances its intellectual property protection and strengthens its core competitiveness through technological innovation [1][2]. Summary by Sections Patent Details - The patent is titled "A Method for Detecting the Fingerprint Spectrum of Ginkgo Biloba Decoction" with certificate number 8210031 [1]. - The patent was granted to Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company [1]. - The patent application was filed on June 19, 2023, and the authorization announcement date is August 29, 2025 [1]. Technological Significance - The patented technology allows for comprehensive detection of the types and quantities of chemical components in ginkgo biloba, establishing a fingerprint spectrum method [1]. - This method will provide a basis for the use of high-quality medicinal materials in product production, ensuring product quality [1]. Impact on Company Operations - The acquisition of this patent is not expected to have a significant impact on the company's production and operations but will enhance the company's intellectual property protection system [2]. - The technology is anticipated to be utilized in the production of new drug products, improving the stability and effectiveness of the company's offerings [1][2].

证券代码：002873 证券简称：新天药业 公告编号：2025-052 贵阳新天药业股份有限公司 关于取得发明专利证书的公告 专利号：ZL 2023 1 0723330.2 授权公告号：CN 116718700 B 专利申请日：2023 年 06 月 19 日 授权公告日：2025 年 08 月 29 日 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）的全资子公司上海硕方医 药科技有限公司于近日收到国家知识产权局颁发的一项发明专利证书，具体情况 如下： 发明专利名称：一种检测白果水煎液指纹图谱的方法及其指纹图谱 证书号：第 8210031 号 发明名称：一种检测白果水煎液指纹图谱的方法及其指纹图谱 专利权人：上海硕方医药科技有限公司 地址：201499 上海市奉贤区望园路 1888 号 1 幢 5 层 发明人：韩豫；王亚茹；成亮；魏茂陈 董事会 2025 年 9 月 3 日 2 申请日时申请人：上海硕方医药科技有限公司 申请日时发明人：韩豫；王亚茹；成亮；魏茂陈 上述发明专利为公司自主技术创新，"一种检测白果水煎液 ...

Market Overview - The Chinese medicine sector experienced a decline of 1.31% on September 3, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Xiangxue: Closed at 10.93, up 2.44% with a trading volume of 268,100 shares [1] - Guizhou Sanli: Closed at 12.80, up 1.43% with a trading volume of 84,000 shares [1] - Weikang Pharmaceutical: Closed at 22.99, up 1.10% with a trading volume of 78,800 shares [1] - Significant decliners included: - Xinda Pharmaceutical: Closed at 11.53, down 5.72% with a trading volume of 156,000 shares [2] - Zhendong Pharmaceutical: Closed at 8.21, down 4.53% with a trading volume of 675,200 shares [2] - Tailong Pharmaceutical: Closed at 6.72, down 4.00% with a trading volume of 294,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 829 million yuan from institutional investors, while retail investors contributed a net inflow of 679 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Guizhou Sanli had a net inflow of 17.47 million yuan from institutional investors, but a net outflow of 13.66 million yuan from retail investors [3] - Weikang Pharmaceutical experienced a net inflow of 8.62 million yuan from institutional investors, while retail investors withdrew 9.30 million yuan [3] - Other notable stocks with significant capital movements include: - ST Xiangxue: Net inflow of 2.50 million yuan from institutional investors [3] - Yunnan Baiyao: Net inflow of 2.27 million yuan from institutional investors [3]

Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Shanghai Shuo Fang Pharmaceutical Technology Co., Ltd., has received a patent for a method to detect the fingerprint spectrum of ginkgo biloba decoction, which will enhance the company's intellectual property protection and core competitiveness [1] Summary by Relevant Categories Patent Information - The patent certificate (No. 8210031) was issued by the National Intellectual Property Administration, with the application date on June 19, 2023, and the authorization announcement date set for August 29, 2025 [1] Product Quality Assurance - The patented method allows for comprehensive detection of the chemical components of ginkgo biloba, providing a basis for ensuring product quality, which will be utilized in the production of related new drugs [1] Impact on Company Operations - While the patent does not have a significant immediate impact on the company's production and operations, it contributes positively to the enhancement of the intellectual property protection system [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on August 28, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Buchang Pharmaceutical (603858) with a closing price of 20.02, up 5.59% and a trading volume of 325,000 shares, totaling 654 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 20.40, up 5.37% with a trading volume of 159,300 shares, totaling 324 million yuan [1] - Jilin Aodong (000623) closed at 20.34, up 1.75% with a trading volume of 239,000 shares, totaling 479 million yuan [1] - Conversely, significant decliners included: - Xinda Pharmaceutical (002873) with a closing price of 12.00, down 4.76% and a trading volume of 304,000 shares, totaling 364 million yuan [2] - Qidi Pharmaceutical (000590) closed at 12.22, down 4.61% with a trading volume of 221,600 shares, totaling 274 million yuan [2] - Kangjia Pharmaceutical (600557) closed at 17.22, down 4.39% with a trading volume of 313,700 shares, totaling 537 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 1.134 billion yuan from institutional investors, while retail investors contributed a net inflow of 930 million yuan [2] - Key stocks with significant capital flow included: - Zhendong Pharmaceutical (300158) with a net inflow of 67.58 million yuan from institutional investors [3] - Jilin Aodong (000623) with a net inflow of 13.62 million yuan from institutional investors [3] - Tianmu Pharmaceutical (600671) with a net inflow of 7.33 million yuan from institutional investors [3]

Group 1 - The stock price of Xintian Pharmaceutical is reported at 12.81 yuan, down 0.50 yuan or 3.76% from the previous trading day [1] - The stock reached a high of 13.47 yuan and a low of 12.78 yuan during the trading session, with a trading volume of 391,500 hands and a transaction amount of 508 million yuan [1] - Xintian Pharmaceutical operates in the traditional Chinese medicine industry, focusing on the research, development, production, and sales of traditional Chinese medicine and chemical drugs [1] Group 2 - On August 26, the company hosted a research meeting with several institutions, including Morgan Stanley Fund and Caitong Fund, discussing the progress of its research pipeline [1] - The research information indicates that the company has made progress in the development of modified new drugs for tumor adjuvant therapy [1] - On August 26, the net outflow of main funds from Xintian Pharmaceutical was 66.77 million yuan, accounting for 2.18% of the circulating market value [1] Group 3 - Over the past five trading days, the cumulative net outflow of main funds reached 137 million yuan, representing 4.47% of the circulating market value [1]